CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
📉 CRISPR Therapeutics revenue dropped nearly 90% to $3.5 million in FY 2025 as one-time milestone payments ceased.
💸 The company reported a net loss of approximately $581.6 million and negative free cash flow of $345.9 million for the year.
⚖️ CRISPR maintains a conservative debt-to-equity ratio of 0.2x but relies on Vertex for CASGEVY commercialization.
⚠️ The company is involved in a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core technology.
📉 Analysts from The Motley Fool's Stock Advisor did not include CRISPR Therapeutics in their top 10 stocks list for the current period.
🚀 Despite financial losses, CRISPR has achieved a product approval and is expanding CASGEVY to younger patients.
Bullish Signals
- CRISPR Therapeutics recently achieved its first product approval for CASGEVY, treating sickle cell disease and transfusion-dependent beta thalassemia.
- The company maintains a conservative debt-to-equity ratio of roughly 0.2x and a strong current ratio of 13.3x, indicating robust short-term liquidity.
- CRISPR has built a gene-editing therapy that is commercially successful and expanding its patient reach to younger demographics.
Risk Factors
- Revenue fell by approximately 90% to $3.5 million in FY 2025 as the company transitioned from one-time milestone payments to recurring sales.
- The company reported a substantial net loss of roughly $581.6 million and negative free cash flow of $345.9 million during the fiscal year.
- The company is currently involved in a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core gene-editing technology.
- There is no guarantee that CRISPR will achieve future profitability given its ongoing operating losses and heavy research investments.
Full Analysis
The article compares CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX), highlighting their distinct positions in the gene-editing space. CRISPR is characterized as a research-focused pioneer that recently secured its first product approval for CASGEVY, treating sickle cell disease and beta thalassemia. However, the company faces significant financial headwinds, reporting revenue of nearly $3.5 million for FY 2025—a 90% decrease from the prior year due to the cessation of large one-time milestone payments.
CRISPR Therapeutics reported a net loss of approximately $581.6 million in FY 2025 as it continues heavy investment in its research pipeline. While the company maintains a conservative debt-to-equity ratio of roughly 0.2x and a strong current ratio of 13.3x, its free cash flow was negative at $345.9 million. The article notes that CRISPR relies heavily on Vertex for the commercial success and manufacturing of CASGEVY, raising concerns about potential capital dilution if further funding is required.
Beyond financial metrics, CRISPR faces specific risks including a patent infringement lawsuit initiated by ToolGen in late 2025 regarding its core gene-editing technology. The article also cites that The Motley Fool's Stock Advisor team did not include CRISPR Therapeutics in their list of top 10 stocks to buy now, contrasting this with Vertex Pharmaceuticals, which was recommended for its established commercial success and diversified portfolio.
